Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy
NCT ID: NCT01956799
Last Updated: 2023-02-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2013-05-31
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS
NCT03920657
Effect of Deferasirox on Patients With Cardiac MRI T2* < 20 Msec
NCT00879242
Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients
NCT00303329
Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease
NCT05861453
Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload
NCT00564941
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Diagnosis of Myelodysplasia, myelofibrosis or aplastic anemia
3. transfusion-dependent anemia undergoing chelation therapy with deferasirox or deferoxamine
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondazione Italiana Sindromi Mielodisplastiche-ETS
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daniela Cilloni, MD
Role: PRINCIPAL_INVESTIGATOR
AOU S. Luigi Gonzaga, Regione Gonzole 10, 10043 Orbassano (TO)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ematologia, AO SS. Antonio e Biagio
Alessandria, AL, Italy
Clinica di Ematologia, AOU Ospedale di Torrette
Ancona, AN, Italy
Ematologia con trapianto, AOU Policlinico di Bari
Bari, BA, Italy
Istituto di Ematologia e Oncologia Medica, Policlinico S.Orsola
Bologna, BO, Italy
Ematologia, Spedali Civili
Brescia, BS, Italy
Struttura complessa di Ematologia, ASO S.Croce e Carle
Cuneo, CN, Italy
Cattedra di Ematologia Policlino Careggi
Florence, FI, Italy
Clinica Ematologica, Università di Genova
Genova, GE, Italy
U.O. Clinica Medicina Interna, IRCCS San Martino IST
Genova, GE, Italy
UO Ematologia e CTMO, Ospedale Civile G. da Saliceto
Piacenza, PC, Italy
Ematologia, Università di Padova
Padua, PD, Italy
Struttura Cattedra di Ematologia e CTMO, AOU di Parma
Parma, PR, Italy
Ematologia e Centro Trapianti, Centro di Riferimento Oncologico della Basilicata
Rionero in Vulture, PZ, Italy
Medicina Interna II Divisione di Ematologia, Ospedale S. Luigi Gonzaga
Orbassano, TO, Italy
Ematologia 2, AOU Città della Salute e della Scienza
Torino, TO, Italy
S.C.D.U. Ematologia e Terapie cellulari, Ospedale Mauriziano
Torino, TO, Italy
UOC Ematologia, Ospedale S.Eugenio
Roma, , Italy
Policlinico A.Gemelli
Roma, , Italy
UOC Ematologia, AO S. Giovanni Addolorata
Roma, , Italy
Ematologia, AO S. Andrea
Roma, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FISM-BIOFER12
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.